This author has yet to write their bio.Meanwhile lets just say that we are proud old admin contributed a whooping 84 entries.
February 7, 2020 Impact: Moderate Innovent Biologics and Eli Lilly have announced that the phase 3 ORIENT-11 trial (NCT03607539) in China has met its primary endpoint of progression-free survival (PFS) for the use of Tyvyt (sintilimab) in combination with ALTIMA (pemetrexed) and platinum-based chemotherapy for patients with 1L advanced or recurrent nonsquamous NSCLC without EGFR […]
December 18, 2019 Impact: Moderate Gilead’s Kite subsidiary has announced that it has submitted a BLA for the investigational CAR-T KTE-X19 for the treatment of patients with relapsed or refractory mantle cell lymphoma (R/R MCL). The BLA is based on data from the Phase 2 ZUMA-2 trial which demonstrated an ORR of 93% (CR rate […]
December 5, 2019 Impact: High CymaBay Therapeutics has terminated its phase 2b study of PPARδ agonist, seladelpar, in patients with NASH due to atypical histological findings. Planned, blinded histological assessments of liver biopsies from trial participants revealed histology characterized as an interface hepatitis presentation, with or without biliary injury. Notably, the atypical histological findings were […]
Networking is critical in almost every industry. In the exceptionally competitive field of healthcare, it is paramount. Medical conferences are an excellent source not only for new clinical data, but also for the latest opinions from physicians. This provides an invaluable look at the future trends for the use of both marketed and pipeline products […]
Competitive intelligence (CI) is a critical component of market intelligence, including market segmentation, opportunity, penetration, and more. In the pharmaceutical industry and other dynamic, capital intensive industries, staying up to date on relevant competitors and market actions is critical. This paper covers some of inThought’s best practices in pharma competitive intelligence.
